Evaluation Of Serum and Salivary Mitofusin-1 and Mitofusin-2 and its Association with Periodontal Diseases and Atherosclerotic Cardiovascular Diseases
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- To correlate the ability of Mitofusin-1 and Mitofusin-2 as a potential common Serum and Salivary biomarker for stage III/IV Periodontitis and risk of developing Atherosclerotic cardiovascular disease
研究概览
简要总结
In Periodontal diseases, mitochondrial dynamics are influenced in several ways such as reduced energy production and increased production of Reactive oxygen species(ROS) Dysregulated mitochondrial dynamics also affect the apoptosis of host cells and immune cells, impacting the overall homeostasis in the periodontal dysbiotic environment And In atherosclerosis, Mitochondrial dysfunction influenced in increased ROS production and oxidative damage. Disrupted mitochondrial dynamics in endothelial cells impair nitric oxide bioavailability, worsening endothelial dysfunction, a critical early event in early plaque formation.Mitochondrial dynamics are influencing in regulation of inflammation and plays a crucial role in both periodontal and cardiovascular diseases. Dysfunctional mitochondrial dynamics can lead to increased oxidative stress and inflammation, which are key drivers in the pathogenesis of both diseases .Mitochondrial dysfunction is linked to Mitofusin proteins, namely Mitofusin-1 and Mitofusin-2. Modulating mitochondrial fusion through these proteins may influence the release of inflammatory mediators Alterations in the levels of Mitofusin-1 and Mitofusin-2 could impact cellular susceptibility to apoptosis, potentially affecting overall tissue integrity in both periodontitis and cardiovascular diseases.Hence , we aim to assess, compare and correlate the ability of MFN1 & MFN2 as a potential common Serum and Salivary biomarker for stage III/IV Periodontitis and risk of developing Atherosclerotic cardiovascular diseases.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 35.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Inclusion criteria for healthy individuals: Based on the classification system introduced by Kornman and Tonetti et al,
- •Pristine periodontal health: · No bleeding on probing.
- •Â· Normal gingival sulcus depth.
- •Â· Normal bone heights.
- •Â· Controlled modifying factors.
- •Â· Controlled predisposing factors.
- •2.Clinical periodontal health (intact periodontium): · No or minimal bleeding on probing.
- •IInclusion criteria for Stage III/IV Periodontitis: Based on the classification system introduced by Kornman and Tonetti et al,
- •1.Stage III: • Interdental clinical attachment loss at site of greatest loss ≥ 5mm.
- •â€¢ Radiographic bone loss extending to middle or apical third of root • Tooth loss due to periodontitis ≤ 4 teeth.
- •â€¢ Probing depth ≥ 6mm.
- •â€¢ Extent: Greater than 30% of teeth involved (Generalized) 2.Stage IV: • Interdental clinical attachment loss at site of greatest loss ≥ 5mm.
- •â€¢ Extent: Greater than 30% of teeth involved (Generalized) Atherosclerosis in this study is defined as an event of Acute Myocardial Infarction, Acute coronary syndrome, patients with defined coronary artery disease (Coronary angiography) and patients post bypass and post stenting.
- •Patients with aortic aneurysms (pathogenesis –atherosclerosis) Inclusion criteria for cardiovascular patients: 1.History of angina and not consuming lipid lowering drugs(statins) 2.Borderline high to high lipid profile inclusive of total cholesterol, Triglycerides and LDL (As per NCEP-ATP III classification) a.
- •Total cholesterol level above 200 mg/dL b.
- •Triglycerides above 150 mg/dL c.HDL above 60 mg/dL d.LDL above 130mg/dL.
排除标准
- •Patients with immunodeficiency disorders.
- •Patients with other systemic inflammatory conditions like sepsis, pneumonia, pleural effusion, intra-abdominal infections, inflammatory bowel disorders, inflammatory rheumatoid disorders, chronic kidney disease, Diabetes, cancers, COPD, asthma, HIV and hepatitis will be excluded from the study.
- •History of periodontal treatment within the last 6 months.
- •History of antibiotic therapy in the past 3 months.
- •Subjects who are not willing to participate in the study.
结局指标
主要结局
To correlate the ability of Mitofusin-1 and Mitofusin-2 as a potential common Serum and Salivary biomarker for stage III/IV Periodontitis and risk of developing Atherosclerotic cardiovascular disease
时间窗: Baseline
次要结局
未报告次要终点
研究者
Kaviyapriya
SRM Dental College